•
•
•
•
•
•
•
•
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
307
IPO Date
Nov 6, 2014
Country
US
Industry
Health Care
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 307 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development, and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences; CHS-006, an antibody targeting TIGIT being developed in collaboration with Junshi Biosciences; and one wholly owned preclinical immuno-oncology program, CHS-1000, an antibody targeting ILT4. The firm markets UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States (the U.S). The company also sells CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, in the U.S. The firm also focused on developing Humira, a biosimilar YUSIMRY (adalimumab-aqvh) in the U.S.
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
No data available
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data
Related Stocks
Related Stocks
Stocks being mentioned with CHRS